Bortezomib (Velcade), an anticancer drug commonly used as the standard treatment of multiple myeloma (MM), has been demonstrated to suppress NFκb activation owing to its ability of proteasome inhibition [167]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.